[Fusion protein abatacept. Remission in every 5th TNF-alpha refractory patient].
D000069594:Abatacept; D000938:Antigen-Presenting Cells / Q000187:drug effects; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D008727:Methotrexate / Q000627:therapeutic use; D012008:Recurrence; D013601:T-Lymphocytes / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D018501:Antirheumatic Agents; D018796:Immunoconjugates; D014409:Tumor Necrosis Factor-alpha; D000069594:Abatacept; D008727:Methotrexate